News

Geneva, Switzerland, March 8, 2016 – Amal Therapeutics, a Swiss biotech start-up company developing and progressing therapeutic vaccines in oncology, today announced that it received a grant from the Swiss Commission for Technology & Innovation (CTI) to validate immunotherapies combination treatments. View PDF
GENEVA, December 1, 2015 – Amal Therapeutics SA (“Amal”), a biotechnology company developing active immunotherapies, announced the issuance on November 17, 2015 of the US Patent number 9,187,534 entitled “MULTI-EPITOPIC VACCINE” by the US Patent and Trademark Office (USPTO). This patent covers Amal’s multi-epitopic vaccine technology platform and its use as immunotherapy for the treatment […]
Geneva, Switzerland, October 27, 2015 – Amal Therapeutics SA (“Amal”), a biotechnology company active in cancer immunotherapy announced today the signature of an exclusive patent license agreement with the University of Minnesota for the use of a novel peptide with potent immunostimulatory properties. View PDF
Geneva, Switzerland, September 8, 2015 – Amal Therapeutics, a Geneva based start-up Biotech Company developing and progressing therapeutic vaccines in oncology, announced today that it signed research collaboration agreement with the Oslo University Hospital (OUH)-Radiumhospitalet (Dept of Cellular Therapy). The objective of the collaboration is to validate Amal Therapeutics lead vaccine candidate using human-cells functional […]
Geneva, Switzerland, June 26, 2015 – Amal Therapeutics announced today that part of its recent research findings about a new type of recombinant protein cancer vaccines, will be available on-line on the Cancer Research website on Friday June 26, 2015. View PDF

Pages